Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents

Citations Over TimeTop 15% of 2012 papers

Abstract

NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

Related Papers

• → ADME–Tox in drug discovery: integration of experimental and computational technologies(2003)181 cited
• → Applications of high-throughput ADME in drug discovery(2004)149 cited
• → ADME Optimization and Toxicity Assessment in Early- and Late-Phase Drug Discovery(2009)83 cited
• → Label-free kinetic binding data as a decisive element in drug discovery(2006)27 cited
• → Advantages of Good Drug-like Properties(2008)18 cited